Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.68 |
| ▸ | BRD4 | O60885 | 14/20 | 0.53 |
| ▸ | ERN1 | O75460 | 2/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17581450 | 0.80 | JAK2 (0.73) | JAK2BRD4CREBBPLRRK2CYP2C9 | |
| SCHEMBL5945605 | 0.79 | JAK2 (0.70) | JAK2BRD4ERN1CREBBPLRRK2 | |
| SCHEMBL17581408 | 0.76 | JAK2 (0.62) | JAK2BRD4CYP2C9GSK3B | |
| SCHEMBL24096948 | 0.75 | JAK2 (0.66) | JAK2BRD4ERN1CREBBPLRRK2 | |
| SCHEMBL5953047 | 0.73 | MAP2K4 (0.49) | — | |
| SCHEMBL13183133 | 0.72 | HTR1D (0.43) | JAK2ERN1DYRK1A | |
| SCHEMBL17581420 | 0.72 | JAK2 (0.61) | JAK2BRD4ERN1CREBBPLRRK2 | |
| SCHEMBL13183156 | 0.72 | JAK2 (0.61) | JAK2GSK3BDYRK1A | |
| SCHEMBL12515273 | 0.72 | DYRK1A (0.40) | JAK2GSK3BDYRK1A | |
| SCHEMBL17581452 | 0.72 | JAK2 (0.60) | JAK2BRD4CREBBPCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055235-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2019-02-21 | — | — | US | disclosed |
| WO-2016097870-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055235-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | JAK2 1812/4885BRD4 1/4885ERN1 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.